Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He did his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent three decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of hematology/oncology and Professor of Medicine at the University of Tennessee Health Science center from 2012-2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees including breast cancer.
Dr. Schwartzberg has published nearly 300 peer reviewed manuscripts, book chapters and monographs. He is founding editor in chief of the Elsevier website PracticeUpdate Oncology and founding editor in chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine and patient reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Positions:
Medical Director, West Cancer Center, Memphis, Tennessee
Chief Medical Officer, OneOncology
Degrees:
State University of New York, BA and MS
New York Medical College, MD, FACP
Postgraduate Training:
Intern, North Shore University Hospital, Manhasset, NY
Fellow in medical oncology/hematology, Memorial Sloan-Kettering Cancer Center
Board Certifications:
Medical oncology
Hematology
Clinical Interests:
Medical oncology/hematology
Disclosures
He is a consultant for Amgen, Pfizer, Helsinn, Genentech, BMS, Myriad, AstraZeneca, Spectrum, and Napo.
He is also on the advisory board for Genomic Health Research Funding (Institution): Amgen and DSMB: Bayer
Recent Contributions to PracticeUpdate:
- Growth Factors and Febrile Neutropenia
- Pathological Response and Survival in TNBC After Neoadjuvant Carboplatin + Docetaxel
- PARP Inhibitors and Carboplatin for Neoadjuvant Triple Negative Breast Cancer Treatment—A West Cancer Center Perspective
- Long-Term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy in Metastatic Triple-Negative Breast Cancer
- Talazoparib in Patients With Advanced Breast Cancer and a Germline BRCA Mutation
- Psychosocial Outcomes of Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer
- Ovarian Stimulation for IVF and Risk of Primary Breast Cancer in BRCA1/2 Mutation Carriers
- Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
- ASCO 2018: New Evidence and Implications for Integrating NEPA for CINV